Myeloma Paper of the Day, June 16th, suggested by Robert Orlowski
Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: EMMY study of patients retreated with anti-CD38 shows median PFS of 5.1 months (23.6 in patients sensitive to anti-CD38 vs. 4.6 if non-sensitive; median OS 17.3 months for all patients (14.8 mos in non-sensitive vs. NR in sensitive).”
Title: Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study
Authors: Alexis Talbot, Cyrille Hulin, Aurore Perrot, Margaret Macro, Karim Belhadj Merzoug, Mohamed Mohty, Arthur Bobin, Lionel Karlin, Salomon Manier, Laure Vincent, Abderrazak El Yamani, Wajed Abarah, Regis Kaphan, Thomas Chalopin, Daniel Ré, Adrienne de Labarthe, Olivier Fitoussi, Chanaz Lounis, Ronan Garlantezec, Olivier Decaux
You can read the Full Article in Clinical Lymphoma, Myeloma and Leukemia.
More posts featuring Robert Orlowski.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023